{
  "ptid_time": "002_S_0729_2007-09-05",
  "img_path": "/data/qiuhui/data/adni/images/002_S_0729/2007-09-05/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 19,282 mm³, 13.7% below the reference mean. With a Z-score of -0.34 (36.6th percentile), this represents normal volume ; hippocampal volume measures 5,580 mm³, 27.4% below the reference mean. With a Z-score of -3.07 (0.1th percentile), this represents profound atrophy; whole brain volume measures 915,859 mm³, 11.0% below the reference mean. With a Z-score of -1.37 (8.5th percentile), this represents mild atrophy; entorhinal cortex volume measures 2,278 mm³, 41.5% below the reference mean. With a Z-score of -3.21 (0.1th percentile), this represents profound atrophy; fusiform gyrus volume measures 17,016 mm³, 6.6% below the reference mean. With a Z-score of -0.74 (23.0th percentile), this represents normal volume ; middle temporal gyrus volume measures 16,728 mm³, 18.5% below the reference mean. With a Z-score of -1.64 (5.0th percentile), this represents moderate atrophy. ",
  "text_data": "Age is 66.1 years. Gender is Female. Education: 16 years. MMSE: 23.0. Logical Memory: 0.0. APOEε4 alleles: 1.0. Biomarker levels: Amyloid beta: 785.40 pg/mL (normal ); Total tau: 308.40 pg/mL (normal ); Phosphorylated tau: 29.71 pg/mL (mild elevated). ",
  "true_diagnosis": "Diagnosis: AD.",
  "gpt_diagnosis": "**Reasoning:** The patient shows profound atrophy in the hippocampus and entorhinal cortex, which are key regions affected in Alzheimer's disease (AD), along with moderate atrophy in the middle temporal gyrus. The MMSE score of 23 suggests mild cognitive impairment, and the mildly elevated P-tau (a biomarker for AD) further supports neurodegenerative changes. However, Aβ is normal, which may indicate early-stage AD or a non-AD tauopathy.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely prodromal Alzheimer’s given hippocampal/entorhinal atrophy and P-tau elevation, but Aβ-negative status introduces some uncertainty).  \n\n**Confidence:** **Medium** (due to conflicting biomarkers—normal Aβ but elevated P-tau—and the need for longitudinal follow-up to confirm progression).",
  "timestamp": "2025-07-25T20:04:49.466865"
}